All In Biotech

Drug Trial Radar · NCT06319456

A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib vs Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 344 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

344

Planned (sponsor's estimate)

Start

Apr 7, 2024

Primary completion

Aug 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.

Conditions

  • CLL/SLL

Interventions

  • Lisaftoclax (APG-2575)Drug

    QD, oral administration, every 28 days for a dosing cycle.

  • AcalabrutinibDrug

    BID, oral administration, every 28 days for a dosing cycle.

  • FludarabineDrug

    Every 28 days for a treatment cycle, administration of 6 cycles.

  • Cyclophosphamide,CTXDrug

    Every 28 days for a treatment cycle, administration of 6 cycles.

  • RituximabDrug

    Every 28 days for a treatment cycle, administration of 6 cycles.

  • ChlorambucilDrug

    Every 28 days for a treatment cycle, administration of 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progress Free Survival (PFS)Time frame: Up to 1 year

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China · Not yet recruiting

  • Henan Provincial Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Second Xiangya Hospital of Center South University

    Changsha, Hunan, China · Not yet recruiting

  • Tongji Hospital of Tongji University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Hematology Hospital of the Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.